New immune cell therapy tested to stop Leukemia's return
NCT ID NCT05535855
Summary
This early-stage trial is testing the safety of a new CAR T-cell therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL). It is for patients who are in their first remission but still have tiny, hard-to-detect amounts of cancer cells. The main goal is to find a safe dose and see if this personalized immune cell treatment can help prevent the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.